A study of biomarkers that predict efficacy of or resistance to trastuzumab emtansine for patients with HER2-positive non-small cell lung cancer
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- 04 Dec 2017 Results published in the Journal of Thoracic Oncology
- 18 Oct 2017 Results (n=15) presented at the 18th World Conference on Lung Cancer.
- 18 Oct 2017 According to results presented at the 18th World Conference on Lung Cancer, study was early terminated due to the limited efficacy.